Marathon Asset Management Stakes Significant Claim in Cinemark with 300,000-Share New Position

The Move

Marathon Asset Management LP has taken a noteworthy step into the theatrical exhibition sector, establishing a new position encompassing 300,000 Cinemark shares valued at $8.41 million as of late September 2025, per an SEC filing from November 17. For this relatively compact fund managing $75.12 million in reportable U.S. equities, this new position carries considerable weight—commanding 11.19% of its 13F assets under management and immediately becoming the second-largest equity holding in the portfolio.

Portfolio Composition Reveals Investment Priorities

The latest filings paint a picture of Marathon’s sector bets. The fund’s top five holdings now break down as follows:

• GrafTech International dominates at $27.1 million (36.1% of AUM)
• Cinemark anchors the entertainment exposure at $8.4 million (11.2% of AUM)
• UnitedHealth Group provides healthcare diversification with $4.3 million (5.8% of AUM)
• John Hancock High Yield ETF contributes $3.3 million (4.4% of AUM)
• Advanced Micro Devices rounds out tech exposure at $3.2 million (4.3% of AUM)

What Cinemark Represents

Cinemark operates as one of the Americas’ leading multiplex exhibitors, controlling 5,868 screens across the United States, South America, and Central America. The business draws revenue streams from theatrical ticket sales, concession operations, and in-venue advertising. On paper, the company carries a $3.43 billion market capitalization with trailing-twelve-month revenue of $3.15 billion and net income of $154.8 million.

The Financial Picture Behind the New Position

Marathon’s conviction appears anchored in tangible signs of operational resilience. Through the first nine months of 2025, Cinemark delivered $107 million in net income, though this represented a notable pullback from prior-year levels. More tellingly, the company successfully retired its remaining pandemic-era convertible debt burden. In Q3, management authorized a fresh $300 million share buyback authorization and lifted the quarterly dividend by 12.5%—moves that signal confidence in cash generation and commitment to shareholder returns.

Market Context

As of mid-November 2025, Cinemark shares traded at $29.59, having declined 6.69% over the trailing twelve months and underperforming the S&P 500 by approximately 19 percentage points. This valuation backdrop may have created the opportunity Marathon seized.

The Investment Thesis

For a fund operating with fewer than 20 total positions, allocating more than 10% of assets to a new position signals meaningful conviction. Marathon’s move appears to rest on a wager that theatrical entertainment remains viable for audience spending and that Cinemark leads the competitive landscape. The theater operator’s demonstrated profitability even amid rising cost pressures, debt reduction achievements, and capital return initiatives collectively paint a picture of a company executing a turnaround or consolidating stability—positioning worth backing in Marathon’s portfolio framework.